Switch theme
Sign up to access all valuation multiples
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. Its research and development activities for all IVD products: Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer. Its product AF-1200 Fluorescence Immunoassay Analyzer, AF-100 Fluorescence Immunoassay Analyzer, AF-100S Fluorescence Immunoassay Analyzer, AF-100C Fluorescence Immunoassay Analyzer.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anbio Biotechnology has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Anbio Biotechnology achieved revenue of $6.7M and an EBITDA of $2.3M.
Anbio Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anbio Biotechnology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $23.5M | $6.7M | XXX | XXX | XXX |
| Gross Profit | $2.5M | $12.6M | XXX | XXX | XXX |
| Gross Margin | 11% | 187% | XXX | XXX | XXX |
| EBITDA | $10.0M | $2.3M | XXX | XXX | XXX |
| EBITDA Margin | 43% | 34% | XXX | XXX | XXX |
| Net Profit | $2.5M | $10.0M | XXX | XXX | XXX |
| Net Margin | 11% | 149% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Anbio Biotechnology's stock price is $6.
Anbio Biotechnology has current market cap of $281M, and EV of $271M.
See Anbio Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $271M | $281M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Anbio Biotechnology has market cap of $281M and EV of $271M.
Anbio Biotechnology's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Anbio Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Anbio Biotechnology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $271M | XXX | XXX | XXX |
| EV/Revenue | 40.4x | XXX | XXX | XXX |
| EV/EBITDA | 119.6x | XXX | XXX | XXX |
| P/E | 124.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 301.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnbio Biotechnology's NTM/LTM revenue growth is n/a
Anbio Biotechnology's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Anbio Biotechnology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Anbio Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Anbio Biotechnology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -71% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -77% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anbio Biotechnology acquired XXX companies to date.
Last acquisition by Anbio Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Anbio Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Anbio Biotechnology founded? | Anbio Biotechnology was founded in 2021. |
| Where is Anbio Biotechnology headquartered? | Anbio Biotechnology is headquartered in United States of America. |
| How many employees does Anbio Biotechnology have? | As of today, Anbio Biotechnology has 27 employees. |
| Who is the CEO of Anbio Biotechnology? | Anbio Biotechnology's CEO is Mr. Michael Lau. |
| Is Anbio Biotechnology publicy listed? | Yes, Anbio Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Anbio Biotechnology? | Anbio Biotechnology trades under NNNN ticker. |
| When did Anbio Biotechnology go public? | Anbio Biotechnology went public in 2025. |
| Who are competitors of Anbio Biotechnology? | Similar companies to Anbio Biotechnology include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Anbio Biotechnology? | Anbio Biotechnology's current market cap is $281M |
| What is the current revenue growth of Anbio Biotechnology? | Anbio Biotechnology revenue growth between 2023 and 2024 was -71%. |
| Is Anbio Biotechnology profitable? | Yes, Anbio Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
